PACIFIC SHUANGLIN BIO-PHAR

Pacific Shuanglin Bio‑Phar’s shares stay flat amid a crowded biotherapeutics market, revealing weak fundamentals and a lack of growth strategy that worries investors.

Pacific Shuanglin Bio‑Pharm (000403.SZ) sees flat Q3 revenue and a 2.89% decline, yet improved cash flow, while peers remain steady on the Shenzhen market.

Explore Pacific Shuanglin Bio‑phar’s latest snapshot: flat trading at CNY 9.75, 9.10 bn market cap, 52‑week highs/lows, and biotech focus.